Gilead Sciences Files 8-K on Financials

TL;DR

Gilead dropped an 8-K on April 25th about their financials - check it for the latest numbers.

AI Summary

Gilead Sciences, Inc. filed an 8-K on April 25, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but serves as a notification of these items.

Why It Matters

This filing indicates that Gilead Sciences is providing updates on its financial performance and condition to the SEC, which is important for investors to stay informed about the company's health.

Risk Assessment

Risk Level: low — The filing is a standard disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — Registrant
• April 25, 2024 (date) — Date of Report
• 333 Lakeside Drive, Foster City, California 94404 (address) — Principal executive offices

FAQ

From the Filing

0000882095-24-000010.txt : 20240425 0000882095-24-000010.hdr.sgml : 20240425 20240425160455 ACCESSION NUMBER: 0000882095-24-000010 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240425 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240425 DATE AS OF CHANGE: 20240425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 24876167 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 gild-20240425.htm FORM 8-K gild-20240425 0000882095 false 0000882095 2024-04-25 2024-04-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 25, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.) 333 Lakeside Drive , Foster City , California (Address of principal executive offices) 94404 (Zip Code) 650 - 574-3000 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Section 2 - FINANCIAL INFORMATION Item 2.02      Results of Operations and Financial Condition. On April 25, 2024 , Gilead Sciences, Inc., a Delaware corporation (“Gilead”), issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial statemen